Inventiva shares break through their €3.55 resistance and gain 3%
The Burgundy-based biotech specialising in fibrotic and metabolic diseases extends its autumn rebound in a well-oriented Parisian market. The stock posts one of the best performances in the index and moves above a technical threshold observed for several weeks.
A resistance level broken intraday and a stock well ahead of its short-term averages
Inventiva shares gained 3.14% to €3.62 intraday, while the SBF 120 rose 0.70%. This gain places it in second position in the index, behind Viridien. The stock broke upward through its €3.55 resistance, the highest level of the last 30 sessions, and is holding above it: this threshold now becomes its support.
The move extends a 26.4% rebound over one month, leaving the price 11.23% above its 20-day moving average (MM20). The 200-day moving average (MM200), at €4.07, remains however above the price, with a gap of 11.18%.
Jefferies lowers its target to €6.20 but maintains its buy rating
On November 10, Jefferies lowered its price target from €7.50 to €6.20, while keeping its buy recommendation. This target implies an upside potential of approximately 71% relative to the day's price. Over one year, the stock shows 10.89%, but it still gives up 11.61% over three months.
On the financial side, during the publication of its H1 2026 results (July 29, 2026), Inventiva had indicated a cash runway limited to the end of the second quarter of 2027 without additional financing. The next technical resistance is at €5.02.
